Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Receivables (2016 - 2025)

Historic Receivables for Ani Pharmaceuticals (ANIP) over the last 16 years, with Q3 2025 value amounting to $252.6 million.

  • Ani Pharmaceuticals' Receivables rose 2864.93% to $252.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $252.6 million, marking a year-over-year increase of 2864.93%. This contributed to the annual value of $221.7 million for FY2024, which is 3680.12% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Receivables is $252.6 million, which was up 2864.93% from $225.7 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Receivables registered a high of $252.6 million during Q3 2025, and its lowest value of $91.9 million during Q1 2021.
  • For the 5-year period, Ani Pharmaceuticals' Receivables averaged around $166.1 million, with its median value being $170.4 million (2022).
  • As far as peak fluctuations go, Ani Pharmaceuticals' Receivables soared by 6234.57% in 2022, and later tumbled by 490.44% in 2023.
  • Ani Pharmaceuticals' Receivables (Quarter) stood at $128.5 million in 2021, then surged by 32.61% to $170.4 million in 2022, then decreased by 4.9% to $162.1 million in 2023, then skyrocketed by 36.8% to $221.7 million in 2024, then increased by 13.93% to $252.6 million in 2025.
  • Its Receivables stands at $252.6 million for Q3 2025, versus $225.7 million for Q2 2025 and $220.3 million for Q1 2025.